Literature DB >> 12377648

Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers.

J Fujimoto1, I Aoki, H Toyoki, S Khatun, T Tamaya.   

Abstract

BACKGROUND: Angiogenesis is essential for development, growth and advancement of solid tumors. ETS-1 has been recognized as a candidate for tumor angiogenic transcription factor. This prompted us to study the clinical implications of ETS-1-related angiogenesis in uterine cervical cancers. PATIENTS AND METHODS: Fifty patients underwent curative resection for uterine cervical cancers. The patients' prognoses were analyzed with a 24-month survival rate. In the tissue of 60 uterine cervical cancers, the levels of ets-1 mRNA, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived endothelial cell growth factor (PD-ECGF) and interleukin (IL)-8 were determined by competitive reverse transcription-polymerase chain reaction using recombinant RNA and enzyme immunoassay, and the localization and counts of microvessels were determined by immunohistochemistry.
RESULTS: There was a significant correlation between microvessel counts and ets-1 gene expression levels in uterine cervical cancers. Immunohistochemical staining revealed that the localization of ETS-1 was similar to that of vascular endothelial cells. The level of ets-1 mRNA correlated with the levels of PD-ECGF and IL-8 among angiogenic factors. Furthermore, the prognosis of the 25 patients with high ets-1 mRNA expression in uterine cervical cancers was extremely poor, while the 24-month survival rate of the other 25 patients with low ets-1 mRNA expression was 92%.
CONCLUSIONS: ETS-1 might be a prognostic indicator as an angiogenic mediator in uterine cervical cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377648     DOI: 10.1093/annonc/mdf248

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  15 in total

1.  Correlated motions and interactions at the onset of the DNA-induced partial unfolding of Ets-1.

Authors:  Hiqmet Kamberaj; Arjan van der Vaart
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

2.  Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors.

Authors:  Snehal Dabir; Amy Kluge; Mohammad A Aziz; Janet A Houghton; Afshin Dowlati
Journal:  Cancer Biol Ther       Date:  2011-07-15       Impact factor: 4.742

3.  The role of ets factors in tumor angiogenesis.

Authors:  Peter Oettgen
Journal:  J Oncol       Date:  2010-05-04       Impact factor: 4.375

4.  Ets-1 regulates energy metabolism in cancer cells.

Authors:  Meghan L Verschoor; Leigh A Wilson; Chris P Verschoor; Gurmit Singh
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

Review 5.  Novel therapeutic strategy for uterine endometrial cancers.

Authors:  Jiro Fujimoto
Journal:  Int J Clin Oncol       Date:  2008-10-23       Impact factor: 3.402

6.  IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals.

Authors:  J H Oh; M-C Cho; J-H Kim; S Y Lee; H J Kim; E S Park; J O Ban; J-W Kang; D-H Lee; J-H Shim; S B Han; D C Moon; Y H Park; D-Y Yu; J-M Kim; S H Kim; D-Y Yoon; J T Hong
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

Review 7.  The biology of the Ets1 proto-oncogene.

Authors:  Jürgen Dittmer
Journal:  Mol Cancer       Date:  2003-08-20       Impact factor: 27.401

8.  Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers.

Authors:  M K Maw; J Fujimoto; T Tamaya
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640

9.  ETS-1 and ETS-2 are upregulated in a transgenic mouse model of pigmented ocular neoplasm.

Authors:  G De la Houssaye; V Vieira; C Masson; F Beermann; J L Dufier; M Menasche; M Abitbol
Journal:  Mol Vis       Date:  2008-10-29       Impact factor: 2.367

10.  Expression of IP-10 related to angiogenesis in uterine cervical cancers.

Authors:  E Sato; J Fujimoto; H Toyoki; H Sakaguchi; S M Alam; I Jahan; T Tamaya
Journal:  Br J Cancer       Date:  2007-05-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.